Evaluation of UMELISA® T4 NEONATAL and UMELISA® T4 using polystyrene plates coated with anti-thyroxine (T4) monoclonal antibodies

Castells, Elisa; González, Ernesto Carlos; Pérez, Pedro L.; Río, L. Del; Tejeda, Yileidis; Perea, Yenitse; Martín, Odalys Rodríguez; Espinosa, Maryeris; Rivero, Jose A.; Frómeta, Amarilys

doi:10.1080/15321819.2017.1392321

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A report in 2019 described the 20-year SUMA ® external QA program, a program limited exclusively to laboratories using the SUMA ® technology and confirmed its relevance in supporting quality NBS [ 1202 ]. Recently research reports have included CF test development [ 1203 , 1204 , 1205 ] and test improvement for CAH [ 1206 ] and CH [ 1207 , 1208 ]. As part of general health screening for newborns, attention has recently been given to piloting a new POC NHS procedure.…”

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transported to a remote testing laboratory began it all. Expansion of NBS to large numbers of asymptomatic congenital conditions flourishes in many settings while it has not yet been realized in others. The need for NBS as an efficient and effective public health prevention strategy that contributes to lowered morbidity and mortality wherever it is sustained is well known in the medical field but not necessarily by political policy makers. Acknowledging the value of national NBS reports published in 2007, the authors collaborated to create a worldwide NBS update in 2015. In a continuing attempt to review the progress of NBS globally, and to move towards a more harmonized and equitable screening system, we have updated our 2015 report with information available at the beginning of 2024. Reports on sub-Saharan Africa and the Caribbean, missing in 2015, have been included. Tables popular in the previous report have been updated with an eye towards harmonized comparisons. To emphasize areas needing attention globally, we have used regional tables containing similar listings of conditions screened, numbers of screening laboratories, and time at which specimen collection is recommended. Discussions are limited to bloodspot screening.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

show abstract

“Application of the ultra micro analytical system (SUMA) technology for the detection of urinary hCG in antidoping control”

Brito¹,

Fis²,

Fernández³

et al. 2018

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

Evaluation of UMELISA® T4 NEONATAL and UMELISA® T4 using polystyrene plates coated with anti-thyroxine (T4) monoclonal antibodies

Abstract: T4: L-Thyroxine; ELISA: Enzyme-linked immunosorbent assay; SUMA: Ultra Micro Analytic System; UMELISA: Ultramicro enzyme-linked immunosorbent assay; TSH: Thyroid-stimulating hormone.

Cited by 2 publications

References 16 publications

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

“Application of the ultra micro analytical system (SUMA) technology for the detection of urinary hCG in antidoping control”

Contact Info

Product

Resources

About